New colorectal cancer drug 'Fruzaqla' is likely to receive approval for commercialization in South Korea.

According to industry sources on the 11th, Takeda Pharmaceuticals Korea’s Fruzaqla (fruquintinib), designated as Global Innovative products on Fast Track (GIFT) by the Ministry of Food and Drug Safety (MFDS), is under review for approval.

GIFT-designated pharmaceuticals are provided various supports for rapid commercialization, including ▲supports for preparing requirements for regulatory approval ▲rolling review process is applied, which enables regulatory review on prepared documents first ▲close communication between the regulatory reviewer and the developing company, such a